טוען...
4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis
BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...
שמור ב:
| הוצא לאור ב: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Group
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|